North America Colorectal Cancer Screening Market Size

North America Colorectal Cancer Screening Market Analysis

The North America Colorectal Cancer Screening Market size is estimated at USD 7.15 billion in 2024, and is expected to reach USD 9.89 billion by 2029, growing at a CAGR of 6.70% during the forecast period (2024-2029).

• The COVID-19 pandemic significantly impacted the studied market, as colorectal cancer screenings declined considerably during the initial pandemic. For instance, according to an article published by Multidisciplinary Digital Publishing Institute (MDPI) in May 2022, a study was conducted in Canada which showed a reduction in the number of colorectal cancer diagnoses during the pandemic compared to the pre-pandemic period.
• Thus, the COVID-19 pandemic significantly impacted the market initially. However, as the pandemic has subsided, colorectal cancer screening procedures are taking place normally, and the market has regained its traction. Hence the North American colorectal cancer screening market is expected to have normal growth during the forecast period of the study.
• Factors such as the increasing prevalence of colorectal cancer, technological advancements, and increasing cancer prevention initiatives are expected to boost the growth of the market during the forecast period of the study.
• The high prevalence of colorectal cancers in the region is one of the major factors driving the market growth, as it is expected to increase the usage of colorectal cancer screening tests. For instance, according to the data published by the Canadian Cancer Society in May 2022, colorectal cancer was expected to be the fourth most commonly diagnosed cancer in Canada in 2022, and it was also expected to be the second leading cause of death from cancer in men and the third leading cause of death from cancer in women. Thus, the high prevalence of colorectal cancer in the country is a significant factor driving the market growth.
• Furthermore, according to an article published by PubMed Central in August 2022, an estimated 37% of colorectal cancer (CRC) patients in the United States are diagnosed at early stages, and approximately 35% and 21% of CRC patients are diagnosed at stage III and IV, respectively. Thus, the increasing need for the early diagnosis of colorectal cancer is expected to boost the usage of colorectal cancer screening tests in the region.
• Additionally, according to an article published by PubMed Central in December 2022, colorectal cancer is considered to be the third most frequent type of cancer in Mexico, and it ranks first in mortality. It has also been observed that a substantial proportion of people with this form of cancer may experience their diagnosis and treatment as traumatic.
• Moreover, colorectal cancer prevention initiatives are also expected to boost the market growth. For instance, according to the data updated by The Ohio State University in 2023, the Ohio Colorectal Cancer Prevention Initiative (OCCPI) is a statewide initiative in Ohio, United States, to screen newly diagnosed colorectal cancer (CRC) patients and their biological relatives for Lynch syndrome, a cancer-causing condition that occurs when a person inherits a mutation in one of four genes.
• Thus, the aforementioned factors, such as the rising prevalence of colorectal cancer and cancer prevention initiatives, are expected to boost the market growth. However, high screening test costs are expected to impede market growth.